Write in a clean editor, then format for npj Breast Cancer in one click — DocuGuru applies the official Springer Nature template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
npj Breast Cancer is a peer-reviewed journal published by Springer Nature, covering Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research. Over its lifetime it has published 1,027 papers, which have received 29,493 citations.
| Publisher | Springer Nature |
|---|---|
| Reference style | Superscript numbered (Nature) Superscript — small raised numerals in the text 1. Smith, A., Jones, B. & Lee, C. A representative article title. npj Breast Cancer 12, 45–58 (2023).
Formats any DOI in npj Breast Cancer style. No sign-up. |
| Publishes research in | Breast Cancer Treatment Studies Cancer Genomics and Diagnostics HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Cancer Cells and Metastasis |
| ISSN | 2374-4677 |
| Citation impact (2-yr) | 5.39 |
| h-index | 77 |
| i10-index | 581 |
| Article processing charge | $3,170 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Memorial Sloan Kettering Cancer Center |
| Journal website | www.nature.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10-15% of incident breast cancers and carries the worst prognosis. TNBC is overrepresented among Black and pre-menopausal women and is associated with significant psychological and treatment-related burdens, including financial…
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease…
Abstract At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). MONARCH 3 is a randomized, phase III, double-blind…
Deleterious inflammation is a primary feature of breast cancer. Accumulating evidence demonstrates that macrophages, the most abundant leukocyte population in mammary tumors, have a critical role at each stage of cancer progression. Such tumor-associated macrophages facilitate neoplastic transformation, tumor immune evasion and the subsequent metastatic cascade. Herein, we discuss the dynamic process whereby molecular and…
Abstract Using quantitative radiomics, we demonstrate that computer-extracted magnetic resonance (MR) image-based tumor phenotypes can be predictive of the molecular classification of invasive breast cancers. Radiomics analysis was performed on 91 MRIs of biopsy-proven invasive breast cancers from National Cancer Institute’s multi-institutional TCGA/TCIA. Immunohistochemistry molecular classification was performed including estrogen receptor, progesterone receptor, human epidermal…
